论文部分内容阅读
目的探讨联合康复新液治疗复治菌阳肺结核的临床效果。方法选取2011年1月-12月复治菌阳肺结核患者120例,随机分为对照组57例,观察组63例。两组患者均采取异烟肼、利福平、吡嗪酰胺、乙胺丁醇、链霉素联合治疗;观察组在此基础上再联用康复新液予以辅助治疗。治疗期间随访患者临床症状、痰菌阴转、病灶吸收情况,并就两组患者治疗效果进行评价。结果治疗2、3、6、8个月时观察组患者痰菌转阴率分别为46.03%、73.02%、90.48%和95.23%,明显高于对照组(26.32%、49.12%、66.66%、84.21%);治疗6个月后胸部CT检查示观察组患者空洞闭合率为73.58%;对照组患者空洞闭合率为52.08%,两组比较差异有统计学意义(χ2=5.016,P=0.025);治疗过程中的不良反应发生率观察组为19.04%,对照组为19.30%,两组比较差异无统计学意义(χ2=0.001,P=0.972)。结论对复治菌阳肺结核联合康复新液进行治疗是一种安全而有效的治疗方法。
Objective To investigate the clinical effect of combined rehabilitation of new liquid in the treatment of retreatment of positive pulmonary tuberculosis. Methods A total of 120 retreatment cases with positive pulmonary tuberculosis from January 2011 to December 2011 were randomly divided into control group (n = 57) and observation group (n = 63). Two groups of patients were taken isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin combined treatment; observation group on this basis, combined with rehabilitation of new liquid to be adjuvant therapy. Follow-up during treatment of patients with clinical symptoms, sputum Yin Yin, lesions absorbed, and the treatment of patients in two groups to evaluate. Results The rates of sputum negative conversion in the observation group were 46.03%, 73.02%, 90.48% and 95.23%, respectively, which were significantly higher than those in the control group (26.32%, 49.12%, 66.66%, 84.21 %). Chest CT examination at 6 months showed 73.58% of patients in observation group and 52.08% of patients in control group. The difference between the two groups was statistically significant (χ2 = 5.016, P = 0.025). The incidence of adverse reactions in the treatment group was 19.04% in the observation group and 19.30% in the control group, with no significant difference between the two groups (χ2 = 0.001, P = 0.972). Conclusion It is a safe and effective treatment for the treatment of dipyridamole positive pulmonary tuberculosis combined with rehabilitation new liquid.